Assessing Fibryga Dosing with ROTEM
For optimal dosing of Fibryga (fibrinogen concentrate) using ROTEM, administer 3-4 g (or 50 mg/kg) when FIBTEM A10 is ≤10 mm or MCF is <7 mm, with each gram of fibrinogen expected to increase FIBTEM by approximately 2 mm.
Understanding ROTEM-Guided Fibrinogen Replacement
Baseline Assessment and Indications
- ROTEM provides real-time assessment of functional fibrinogen contribution to clot formation, making it preferable to laboratory fibrinogen measurement in bleeding patients 1
- Hypofibrinogenemia is the biomarker most predictive of severe postpartum hemorrhage and is often the first coagulation factor to critically decrease during massive blood loss 2, 1
- Fibrinogen supplementation is indicated when there are thromboelastometric signs of a functional fibrinogen deficit or plasma fibrinogen levels <1.5-2.0 g/L in the presence of significant bleeding 2, 3
ROTEM Parameters for Fibryga Dosing
- In trauma patients, a Maximum Clot Firmness (MCF) of 7 mm on ROTEM correlates with a fibrinogen level of approximately 2 g/L 2, 1
- FIBTEM A10 ≤10 mm is considered the threshold for fibrinogen replacement in bleeding patients 4
- For acquired fibrinogen deficiency, the FDA-approved dosing for Fibryga is:
- Adults: 4 g
- Adolescents ≥12 years: 50 mg/kg
- Children <12 years: 70 mg/kg 4
Expected Response to Fibryga Administration
- For every gram of fibrinogen concentrate administered, expect approximately a 2-mm increase in the FIBTEM assay 1
- A single dose of Fibryga significantly increases MCF from baseline, with a mean change of 9.7 mm one hour post-infusion 4
- Fibryga contains a higher concentration of factor XIII (0.2 IU factor XIII per mg fibrinogen) compared to other fibrinogen concentrates, which may enhance clot firmness 1
Practical Algorithm for Fibryga Dosing with ROTEM
Initial Assessment:
Decision to Administer Fibryga:
Initial Dosing:
Post-Administration Monitoring:
Additional Dosing:
Clinical Considerations and Caveats
Efficacy Considerations
- A single dose of Fibryga is often sufficient to correct fibrinogen and FIBTEM A10 only when baseline fibrinogen is >100 mg/dL and FIBTEM A10 is >5 mm 5
- Patients with lower baseline values may require repeated dosing 5
- ROC curve analysis shows that post-treatment fibrinogen levels under 204.5 mg/dL predict the need for massive transfusion 5
Potential Pitfalls
- Laboratory methods to measure fibrinogen concentration may have methodological issues, particularly in the presence of artificial colloids like hydroxyethyl starch 1
- ROTEM provides more reliable assessment of functional fibrinogen in these situations 1
- While thrombotic risk is a theoretical concern with fibrinogen administration, studies have shown that intra-operative fibrinogen administration does not appear to increase thrombotic risk 1
Special Populations
- In pregnancy, fibrinogen levels <200 mg/dL are associated with severe postpartum hemorrhage, suggesting higher target levels may be needed in this population 2
- For women with congenital fibrinogen disorders during pregnancy, maintain fibrinogen levels ≥1 g/L throughout pregnancy and ≥1.5 g/L for labor and delivery 6